The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Axitinib plus avelumab for recurrent/metastatic adenoid cystic carcinoma (R/M ACC): Biomarker analysis of the phase II trial.
 
Camilla Oliveira Hoff
Leadership - Rede D'Or São Luiz (I)
Stock and Other Ownership Interests - Oncostar (I)
Honoraria - Bayer (I); Lilly (I)
Consulting or Advisory Role - Bayer (I); Lilly (I)
Research Funding - Exelixis (I); Lilly (I); Novartis (I)
 
Daniel McGrail
Patents, Royalties, Other Intellectual Property - Pending patents on biomarkers for sensitivity to cancer therapeutics.
 
Yoshitsugu Mitani
No Relationships to Disclose
 
Simon Heeke
Employment - Marker Therapeutics (I)
Honoraria - Qiagen
Consulting or Advisory Role - Boehringer Ingelheim
Speakers' Bureau - AstraZeneca; Guardant Health
Patents, Royalties, Other Intellectual Property - Patent on the Treatment of Lung Cancer
Travel, Accommodations, Expenses - Roche
 
Luana Sousa
No Relationships to Disclose
 
Erison Santos
No Relationships to Disclose
 
Juliana Mota Siqueira
No Relationships to Disclose
 
Kaiyi Li
No Relationships to Disclose
 
Diana Bell
No Relationships to Disclose
 
Mario L. Marques-Piubelli
No Relationships to Disclose
 
Shiaw-Yih Lin
No Relationships to Disclose
 
Adel K. El-Naggar
No Relationships to Disclose
 
Renata Ferrarotto
Consulting or Advisory Role - Answers in CME; Coherus Biosciences; Eisai; Elevar Therapeutics; Labcorp Drug Development; Prelude Therapeutics; Regeneron; Remix Therapeutics; Sanofi/Aventis
Research Funding - Ayala Pharmaceuticals (Inst); Gilead Sciences (Inst); ISA Pharmaceuticals (Inst); Merck Serono (Inst); Pfizer/EMD Serono (Inst); Prelude Therapeutics (Inst); Seagen (Inst); Viracta Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Royalties on UpToDate chapter on olfactory neuroblastoma, ~ 300 dollars per year